The United Kingdom and the United States have finalized a important bilateral deal that will guarantee zero duties on UK pharmaceutical products going into the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost funding on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that tariffs on these crucial exports will be held at nothing for a period of the next three years.
This agreement comes after earlier warnings to dramatically increase import taxes on branded drug imports, with figures mentioned up to one hundred percent.
"This arrangement with the UK strengthens the international landscape for innovative medicines and establishes long-overdue equity to American-British medicine commerce," a release noted.
Trade Impact
Pharmaceuticals represent one of the UK's most significant goods shipped to the United States, which is easily the primary destination for leading UK drugmakers.
Trade data indicate that in the one-year period to the end of last September, the UK shipped pharmaceutical products totaling over eleven billion pounds to the US. This amount made up 17.4% of all goods exports in that period.
"This guarantee secures employment, boosts funding and facilitates the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The agreement includes several specific commitments from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new therapies to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to increase total public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The sum pharmaceutical firms must return to the NHS to control costs will be limited at fifteen percent. In the past, refunds exceeded twenty percent.
Recent Tensions
The pact comes amid a long-running tension between the drug companies and the UK government over drug pricing and regulatory access.
These tensions were intensified by claims that American consumers were paying significantly more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had declined as a proportion of its total funding over the last ten years.
